Skip to content
What's so Great About TMC114? episode artwork

Jun 28, 2008 18 min

What's so Great About TMC114?

from TheBody.com: Podcast Central

TheBody.com interviewed Dr. Cal Cohen, one of the lead researchers who investigated TMC114 (darunavir, Prezista) in clinical trials, to get his take on some of the key questions surrounding this new HIV medication: Why should we be so excited about TMC114? What side effects can it cause? How is it likely to change the way HIVers with multidrug resistance are treated?

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

What's so Great About TMC114?

0:00 18:19

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of TheBody.com: Podcast Central?

This episode is 18 minutes long.

When was this TheBody.com: Podcast Central episode published?

This episode was published on June 28, 2008.

Can I download this TheBody.com: Podcast Central episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.